Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Ovarian Neoplasms 1Neoplasms, Second Primary 1NSCLC 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Kidney Neoplasms 1Gastro Intestinal Stromal Tumor 1Endometrial Neoplasms 1Congenital Abnormalities 1Asymptomatic Brain Metastases 1

Interventions

Whole-Body Irradiation 4Peripheral Blood Stem Cell Transplantation 4Etoposide 4Busulfan 4fludarabine phosphate 3Mycophenolic Acid 3Cyclophosphamide 3Transplantation 2Tacrolimus 2Sirolimus 2Melphalan 2Cyclosporine 2fludarabine 1aldesleukin 1Whole Genome Sequencing 1Valganciclovir 1Tyrosine Kinase Inhibitors 1Tissue Banks 1Therapeutics 1Self Care 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiography, Panoramic 1Positron-Emission Tomography 1Polymerase Chain Reaction 1Patient Reported Outcome Measures 1Methotrexate 1Idarubicin 1Ganciclovir 1Foscarnet 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Congenital Abnormalities × Tyrosine Kinase Inhibitors × 1 year × Clear all
NCT04151342 2025-12-03

CARMA-BROS

University Health Network, Toronto

Recruiting
5,500 enrolled

Congenital Abnormalities, Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡